TERNTerns Pharmaceuticals, Inc.

Nasdaq ternspharma.com


$ 5.30 $ 0.21 (4.13 %)    

Thursday, 02-May-2024 15:59:56 EDT
QQQ $ 429.07 $ 5.38 (1.28 %)
DIA $ 382.31 $ 3.34 (0.88 %)
SPY $ 505.01 $ 4.68 (0.94 %)
TLT $ 88.87 $ 0.38 (0.43 %)
GLD $ 213.12 $ -0.66 (-0.31 %)
$ 5.29
$ 5.19
$ 5.29 x 400
$ 5.31 x 400
$ 5.09 - $ 5.33
$ 3.26 - $ 13.51
497,787
na
376.96M
$ 0.47
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-14-2024 12-31-2023 10-K
2 11-14-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-27-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-07-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 05-14-2021 03-31-2021 10-Q
13 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-neutral-on-terns-pharma-maintains-55-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Terns Pharma (NASDAQ:TERN) with a Neutral and maintains $5.5 price target.

 jmp-securities-reiterates-market-outperform-on-terns-pharma-maintains-15-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Terns Pharma (NASDAQ:TERN) with a Market Outperform and maintains $15 pric...

 terns-pharmaceuticals-announces-data-from-ongoing-phase-1-pharmacokinetic-study-of-allosteric-bcr-abl-inhibitor-tern-701-in-adult-healthy-volunteers-and-highlights-potential-for-competitive-differentiation

Ability to dose TERN-701 without regard to food represents a key potential differentiator within the allosteric BCR-ABL inhibit...

 ubs-maintains-buy-on-terns-pharma-lowers-price-target-to-18

UBS analyst Eliana Merle maintains Terns Pharma (NASDAQ:TERN) with a Buy and lowers the price target from $19 to $18.

 jmp-securities-maintains-outperform-on-terns-pharma-lowers-price-target-to-15

JMP Securities analyst Silvan Tuerkcan maintains Terns Pharma (NASDAQ:TERN) with a Outperform and lowers the price target fr...

 bmo-capital-maintains-outperform-on-terns-pharma-raises-price-target-to-19

BMO Capital analyst Etzer Darout maintains Terns Pharma (NASDAQ:TERN) with a Outperform and raises the price target from $18...

 hc-wainwright--co-reiterates-neutral-on-terns-pharma-maintains-55-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Terns Pharma (NASDAQ:TERN) with a Neutral and maintains $5.5 price target.

 terns-pharma-q4-eps-029-inline

Terns Pharma (NASDAQ:TERN) reported quarterly losses of $(0.29) per share which met the analyst consensus estimate. This is unc...

 terns-pharmaceuticals-secures-fda-orphan-drug-designation-for-tern-701-for-treatment-of-chronic-myeloid-leukemia

TERN-701, the Company's internally discovered allosteric BCR-ABL tyrosine kinase inhibitor (TKI), is in Phase 1 clinical de...

 why-take-two-interactive-software-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter res...

 hc-wainwright--co-maintains-neutral-on-terns-pharma-lowers-price-target-to-55

HC Wainwright & Co. analyst Ed Arce maintains Terns Pharma (NASDAQ:TERN) with a Neutral and lowers the price target from...

 jmp-securities-reiterates-market-outperform-on-terns-pharma-maintains-17-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Terns Pharma (NASDAQ:TERN) with a Market Outperform and maintains $17 pric...

 top-5-health-care-stocks-that-are-ticking-portfolio-bombs

As of Dec. 5, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a...

 why-u-power-shares-are-trading-lower-by-around-54-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of reg...

 saic-reports-q3-results-joins-uber-wallbox-and-other-big-stocks-moving-higher-on-monday

U.S. stocks traded lower, with the Dow Jones index falling more than 100 points on Monday.

 mizuho-maintains-buy-on-terns-pharma-lowers-price-target-to-10

Mizuho analyst Graig Suvannavejh maintains Terns Pharma (NASDAQ:TERN) with a Buy and lowers the price target from $17 to $10.

 recap-terns-pharma-q3-earnings
Recap: Terns Pharma Q3 Earnings
11/14/2023 14:10:05

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION